Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for China Pharma Holdings (CPHI) over the last 15 years, with Sep 2025 value amounting to -$68,702.

  • China Pharma Holdings' Change in Accured Expenses fell 21.64% to -$68,702 in Q3 2025 from the same period last year, while for Sep 2025 it was $762,943, marking a year-over-year increase of 520.43%. This contributed to the annual value of $432,051 for FY2024, which is 67.61% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Change in Accured Expenses is -$68,702, which was down 136.69% from $187,274 recorded in Q2 2025.
  • China Pharma Holdings' Change in Accured Expenses' 5-year high stood at $804,339 during Q4 2022, with a 5-year trough of -$450,887 in Q1 2023.
  • In the last 3 years, China Pharma Holdings' Change in Accured Expenses had a median value of $25,734 in 2023 and averaged $65,710.
  • In the last 5 years, China Pharma Holdings' Change in Accured Expenses spiked by 1,563.75% in 2021 and then crashed by 579.20% in 2022.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Change in Accured Expenses stood at $207,099 in 2021, then surged by 288.38% to $804,339 in 2022, then plummeted by 47.67% to $420,886 in 2023, then skyrocketed by 73.44% to $729,967 in 2024, then decreased by 21.64% to -$68,702 in 2025.
  • Its Change in Accured Expenses was -$68,702 in Q3 2025, compared to $187,274 in Q2 2025 and -$85,596 in Q1 2025.